STOCKS TELEGRAPH

Tag: NASD:GLMD

  • Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development

    Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development

    Shares of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) surged significantly today following a key development announcement. As of the most recent check, GLMD stock was trading at $2.44, reflecting a sharp increase of 55.41%.

    Strategic Partnership to Advance Drug Delivery Innovation

    Galmed Pharmaceuticals disclosed that it has signed a binding term sheet with Entomus s.r.o. to license and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS). This novel technology facilitates the sublingual absorption of peptide-based therapies, notably GLP-1 analogs. A definitive agreement, outlining milestone and royalty payments, is expected to be executed within 90 days.

    Drug effectiveness is frequently reduced by current issues with oral drugs, especially the first-pass hepatic metabolism. In the meanwhile, despite their effectiveness, injectable medications cause discomfort and make it difficult to comply. By avoiding the gastrointestinal tract and allowing direct absorption into the circulation through the mouth mucosa, sublingual administration presents a possible substitute.

    Growing Market Demand for GLP-1 Therapeutics

    GLP-1 receptor agonists, including semaglutide, are increasingly being used in the domains of cancer, cardiovascular disease, and metabolism. Jefferies projects that the worldwide GLP-1 market would reach $120 billion by 2030, mostly due to an increase in type 2 diabetic mellitus (T2DM) and obesity patients. Notably, by 2032, peak sales outside of the US are expected to reach about $20 billion.

    Patents in other significant locations, including as India, Brazil, the GCC countries, Singapore, and South Africa, are scheduled to expire as early as 2026, even if semaglutide maintains intellectual property protection in vital markets like the U.S., Europe, and Japan through 2028–2031. These areas provide substantial economic potential for novel GLP-1 treatments due to the rise in T2DM and obesity prevalence.

    Opening Up New Prospects with an Innovative Semaglutide Formulation

    Galmed hopes to use SEDDS technology to create and market a sublingual version of semaglutide through this arrangement. In comparison to oral semaglutide (Rybelsus), this method may improve bioavailability and allow for dosage reductions while providing a non-invasive, patient-friendly method of administration.

    Galmed (GLMD) also plans to expedite development by seeking faster regulatory paths, such as the 505(b)(2) approach. A major unmet need in the field of GLP-1 treatment may be filled by the novel delivery strategy, which may offer better glycemic control, less side effects, and enhanced pharmacokinetic consistency.

  • Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward

    Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward

    After strategic market research indicated that there was increasing demand for treatments for breast cancer, Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) saw a sharp increase in share price. This encouraging research helped the stock conclude the previous trading session at $9.35, indicating an 11.31% rise. This pattern emphasizes the increasing positivity around biotech businesses that are creating cutting-edge cancer therapies.

    Market Growth Predictions for Metastatic Breast Cancer

    The global market for treatments for metastatic breast cancer is expected to increase significantly, with a compound annual growth rate (CAGR) of 10.4% predicted to reach an estimated $41.74 billion by 2030, Strategic Market Research revealed in a recent report.

    Chemotherapy and radiation therapy are two common therapies for metastatic breast cancer that work by preventing the development of tumors. But since hormone treatment particularly targets cancer cell growth, it has shown to be the most successful strategy.

    Key Drivers of Market Expansion

    The anticipated growth of the metastatic breast cancer treatment market is propelled by several factors, including the integration of advanced technologies and an escalating demand for effective therapies. Strategic Market Research highlights that increased investments in research and development, coupled with heightened awareness of cancer diagnostics, are expected to significantly boost market expansion. Furthermore, improved reimbursement policies and government initiatives aimed at funding innovative treatments are also likely to enhance the market landscape for companies from the likes of Galmed Pharmaceuticals.

    Galmed’s Strategic Initiatives

    Galmed Pharmaceuticals is also planning expanding its drug development activities, following encouraging results from the Open-Label segment of its Phase 3 NASH study and new insights into SCD1 as a key metabolic signaling hub. The company intends to introduce two additional programs over the next two years.

    The first will explore novel Aramchol-based drug combinations to address resistance in standard oncological treatments for advanced colorectal and hepatic cancers. The second program aims to investigate mechanisms targeting cardiac fibrosis, a significant concern in various cardiovascular diseases. New data from in-vitro and ex-vivo studies is expected to be released in the fourth quarter of 2024.

    Galmed Pharmaceuticals (GLMD) is strategically positioning itself to tackle pressing public health challenges while leveraging cutting-edge methodologies to enhance drug development and address significant health burdens worldwide.